MORE►
AI drug discovery
Lantern Pharma CEO Panna Sharma [Courtesy: Lantern Pharma]
Dallas Biotech Launches Open-Access AI Tool Targeting One of Brain Drug Discovery’s Toughest Hurdles
by Quincy Preston | Aug 20, 2025
With just 2% to 6% of small-molecule drugs able to cross the blood-brain barrier, researchers and drugmakers face steep odds. Lantern Pharma’s tool, the company’s CEO says, could be “a paradigm shift” in developing treatments for conditions ranging from brain cancers to Parkinson’s disease.
by Maddie Preston |
Aug 8, 2025
The funding supports UT Arlington researcher Junzhou Huang, whose team recently ranked first in protein contact prediction and placed sixth overall in an international AI challenge competing against Google DeepMind, the University of Washington, and others.
MORE►
